Member access

4-Traders Homepage  >  Shares  >  Swiss Exchange  >  Actelion Ltd    ATLN   CH0010532478

ACTELION LTD (ATLN)

39
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Actelion Ltd
Develops, produces and markets pharmaceutical drugs

Actelion Ltd. operates as a holding company with interests in developing, producing and marketing pharmaceutical drugs.

It is a biopharmaceutical company, which focuses on the drug discovery, development, registration, production and commercialization of innovative drugs for diseases with significant unmet medical needs.

The company's portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications.

It has treatments for specialist diseases, including Type 1 Gaucher disease, Niemann-Pick type C disease, digital ulcers in patients suffering from systemic sclerosis and mycosis fungoides in patients with cutaneous T-cell lymphoma.

The company products include Tracleer (bosentan), Zavesca (miglustat), Ventavis (iloprost), Veletri (epoprostenol for injection), Valchlor and Opsumit (macitentan).

Actelion was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Mueller, and Thomas Widmann on December 17, 1997 and is headquartered in Allschwil, Switzerland.
Sales per Businesses
20122013Delta
CHF (in Million)%CHF (in Million)%
Drugs1,728100%1,786100% +3.21%
Sales per Regions
20122013Delta
CHF (in Million)%CHF (in Million)%
United States709.6541.1%767.9643% +7.59%
Europe616.9635.7%632.0635.4% +2.39%
Rest of the World368.8121.3%356.6620% -3.41%
Switzerland32.981.9%29.061.6% -13.52%
Managers
NameAgeSinceTitle
Jean-Paul Clozel, MD591997Chief Executive Officer & Executive Director
Jean-Pierre Garnier PhD, MBA672011Chairman
Otto Schwarz, PhD592008Chief Operating Officer & Executive Vice President
André C. Muller, MBA512013Chief Financial Officer & Executive Vice President
Martine Clozel, MD591997Chief Scientific Officer & Senior Vice President
Guy Braunstein MD, PhD582009Executive VP & Head-Global Clinical Development
Michael Jacobi, PhD612009Non-Executive Director
Werner Henrich71-Non-Executive Director
Jean Pierre Malo CFA, MBA60-Non-Executive Director
Juhani Anttila60-Non-Executive Director
Shareholders
NameShares%
BlackRock Investment Management (UK) Ltd. 6,169,7635.41%
Rudolf Maag, MBA 6,067,3055.32%
Jean-Paul Clozel, MD 5,281,5444.63%
Orbis Investment Management Ltd. 3,568,4893.13%
Fidelity Management & Research Co. 3,290,3302.88%
Actelion Ltd. 2,997,7972.63%
Bellevue Asset Management AG 2,522,1292.21%
Wellington Management Co. LLP 2,512,0062.20%
Norges Bank Investment Management 2,310,0202.02%
Artisan Partners LP 2,238,9981.96%
Holdings
NameShares%Valuation
Actelion Ltd (ATLN) 2,997,7972.63%352,331,351 USD
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Biotechnology & Medical Research
Growth (Revenue) Profitability
ACTELION LTD
SHANGHAI RAAS BLO..
-
MEDIVATION INC
AGIOS PHARMACEUTI..
RECEPTOS INC
NPS PHARMACEUTICA..
INTERCEPT PHARMAC..
GENMAB A/S
AVANIR PHARMACEUT..
HUALAN BIOLOGICAL..
BEIJING SL PHARMA..
BLUEBIRD BIO INC
TONGHUA DONGBAO P..
MANNKIND CORPORAT..
DYAX CORP.
CLOVIS ONCOLOGY I..
PTC THERAPEUTICS,..
NEUROCRINE BIOSCI..
ACORDA THERAPEUTI..
CHINA BIOLOGIC PR..
Sector Biotechnology & Medical Research
Company contact information
16 Gewerbestrasse
CH-4123 Allschwil, Basel-Landschaft
Switzerland

Phone : +41 61 565 65 65
Fax : +41 61 565 65 00
Internet : http://www.actelion.com
Markets and indexes
- SIX Swiss Exchange
- Main Standard
- SMI /
Stock Exchange Codes
- ISIN Code :  CH0010532478
- Bloomberg Code :  ATLN:VX
- Reuters Code :  ATLN.VX
- Datastream Code :  S:ATLN
© 2014 Factset    © 2014 Cofisem   
Dynamic quotes  
ON
| OFF